Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CDC ACIP Unanimously Votes to Provisionally Recommend Merck?s VAXNEUVANCE?

10/20/2021 | 07:07pm EST

Merck & Co., Inc. announced the U.S. Centers for Disease Control and Prevention?s (CDC?s) Advisory Committee on Immunization Practices (ACIP) unanimously voted in favor of updates to pneumococcal vaccination recommendations for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions (e.g., chronic conditions such as diabetes, chronic heart disease, chronic lung disease, or chronic liver disease, as well as HIV, an immunocompromising condition) or other disease risk factors (e.g., smoking, alcoholism). In both groups, the ACIP voted to provisionally recommend vaccination either with a sequential regimen of VAXNEUVANCEfollowed by PNEUMOVAX, or with a single dose of 20-valent pneumococcal conjugate vaccine. These updates would apply to adults who have not previously received a pneumococcal conjugate vaccine or whose previous pneumococcal vaccination history is unknown. PNEUMOVAX 23 is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F), in persons 50 years of age or older and persons aged =2 years who are at increased risk for pneumococcal disease; PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. PNEUMOVAX 23 is contraindicated in individuals with a history of a hypersensitivity reaction to any component of PNEUMOVAX 23.


ę S&P Capital IQ 2021
All news about MERCK & CO., INC.
12/03FDA Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Treatment for Adult and Pedi..
BU
12/03Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19
DJ
12/03Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupira..
AQ
12/03Canada Signs Deal for 1 Mln Doses of Pfizer Covid Antiviral and 500K Merck's Covid Pill
MT
12/03Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
12/03Bristol-Myers Squibb's Supplemental Biologics License Application for Drug Co-Developed..
MT
12/03KYODO NEWS DIGEST : Dec. 3, 2021 -3-
AQ
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/03Nikkei 225 Gains 1% on Merck Covid-19 Drug Application
MT
12/03U.S. pharma Merck unit seeks Japan's approval of oral COVID drug
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 572 M - -
Net income 2021 12 378 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 15,1x
Yield 2021 3,54%
Capitalization 185 B 185 B -
EV / Sales 2021 4,24x
EV / Sales 2022 3,55x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,34 $
Average target price 95,25 $
Spread / Average Target 29,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.34%185 253
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641